|
Report Date : |
10.05.2014 |
IDENTIFICATION DETAILS
|
Name : |
LABORATORIOS ASPEN S.A. |
|
|
|
|
Registered Office : |
Remedios 3439/43 (1407) Buenos Aires City |
|
|
|
|
Country : |
Argentina |
|
|
|
|
Date of Incorporation : |
13.05.1985 |
|
|
|
|
Legal Form : |
Public Limited Company |
|
|
|
|
Line of Business : |
Manufacturers and Sale of Medical and Pharmaceutical Products |
|
|
|
|
No. of Employees : |
15 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2014
|
Country Name |
Previous Rating (31.12.2013) |
Current Rating (31.03.2014) |
|
Argentina |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
ARGENTINA - ECONOMIC OVERVIEW
Argentina benefits from rich
natural resources, a highly literate population, an export-oriented
agricultural sector, and a diversified industrial base. Although one of the world's
wealthiest countries 100 years ago, Argentina suffered during most of the 20th
century from recurring economic crises, persistent fiscal and current account
deficits, high inflation, mounting external debt, and capital flight. A severe
depression, growing public and external indebtedness, and an unprecedented bank
run culminated in 2001 in the most serious economic, social, and political
crisis in the country's turbulent history. Interim President Adolfo RODRIGUEZ
SAA declared a default - at the time the largest ever - on the government's
foreign debt in December of that year, and abruptly resigned only a few days
after taking office. His successor, Eduardo DUHALDE, announced an end to the
peso's decade-long 1-to-1 peg to the US dollar in early 2002. The economy
bottomed out that year, with real GDP 18% smaller than in 1998 and almost 60%
of Argentines under the poverty line. Real GDP rebounded to grow by an average
8.5% annually over the subsequent six years, taking advantage of previously
idled industrial capacity and labor, an audacious debt restructuring and
reduced debt burden, excellent international financial conditions, and
expansionary monetary and fiscal policies. Inflation also increased, however,
during the administration of President Nestor KIRCHNER, which responded with
price restraints on businesses, as well as export taxes and restraints, and
beginning in 2007, with understating inflation data. Cristina FERNANDEZ DE
KIRCHNER succeeded her husband as President in late 2007, and the rapid economic
growth of previous years began to slow sharply the following year as government
policies held back exports and the world economy fell into recession. The
economy in 2010 rebounded strongly from the 2009 recession, but has slowed
since late 2011 even as the government continued to rely on expansionary fiscal
and monetary policies, which have kept inflation in the double digits. The
government expanded state intervention in the economy throughout 2012. In May
the Congress approved the nationalization of the oil company YPF from Spain's
Repsol. The government expanded formal and informal measures to restrict
imports during the year, including a requirement for pre-registration and
pre-approval of all imports. In July the government also further tightened
currency controls in an effort to bolster foreign reserves and stem capital
flight.
|
Source
: CIA |
LABORATORIOS ASPEN S.A.
CUIT.: 30-61056222-8
INITIATION OF ACTIVITIES IN 1985. NO PROVIDED FINANCIAL INFORMATION TO
THIRD PARTIES. NO REGISTERED NEGATIVE. APT FOR MODERATE CREDITS AND WITH
ADDITIONAL GUARANTEES.
MEDICAL AND PHARMACEUTICAL PRODUCTS
MANUFACTURERS
SALE
Legal form:
Public limited company
Created: 13/05/1985
Registered: 1985
Duratión: 99 years
End of fiscal year: 31 March
AFIP.: No. 47, Av. Alvarez Jonte 2376, Buenos Aires City.
Mrs. Melisa Olivetto
Legal and operative address: Remedios 3439/43 (1407) Buenos Aires City,
Repúblic of Argentina
Phone:(54-11) 4611-3637
E-mail: lab-aspen@sinectis.com.ar
President:
RABOSTO HUGO
Director: RABOSTO ROY GASTON
Alternate Director: RABOSTO
REGINA GLENSA
Using of signature: President.
RABOSTO HUGO
Argentino, born 03/04/1950, DNI-.8.308952 (CUIT. 20-08308952-1), with addres in
calle Rio de Janeiro 775 P.1o.D Buenos Aires City.
RABOSTO ROY GASTON
Argentino, born 19/12/1980, DNI.28.643625 (CUIT. 20-28643625-1), with addres in
Avda. Scalabrini Ortiz
17, Buenos Aires City.
RABOSTO REGINA GLENDA
Argentina, born 11/11/1985, single, DNI 31.988.117.
The firm in question starts activities in the month of May 1985 as ASPEN
LIMITED LIABILITY COMPANY, and in 1999 changed its name and legal nature,
LABORATORIOS ASPEN SA.
There is no knowledge, that is part of an economic group.
The company not provided financial information to third parties.
REAL ESTATE:
Remedios 3439/43 (1407) Buenos Aires City, Repúblic of Argentina,
surface covered of 2.000 m2.
SHANGAI CHEMATIS (CHINE)
CHEMICAL CENTER S.A. (KOREA)
Payments: 30/60/90 days.
Concept: Normal
As noted in the heading, the firm
manufactures and markets pharmaceutical products and medical specialties,
running in the direction of the signs, building property, commercial and
administrative offices, laboratory, warehouse and other units that make up the
activity.
Since 2006, Laboratorios Aspen SA. has begun to market its portfolio of
products in the global market.
By developing strategic alliances with various prestigious international
laboratories, and distributors, today, products Laboratorios Aspen SA are
marketed in over 20 countries and are developing more than 10 new markets.
Products
---------
Aciteb - Decitabina
Anaskebir - Anastrozol
Bitakebir - Bicalutamida
Carbokebir - Carboplatino
Catepen - Capecitabina
Docekebir - Docetaxel Anhidro
Doxokebir - Doxorubicina ClH
Fludakebir - Fludarabina Fosfato
Gebina - Gemcitabina
Imatib - Imatinib mesilato
Kebir - Oxaliplatino
Kebirtecan - Irinotecan ClH (como trihidrato) Kebirterona Ciproterona Acetato
Kebirzol - Letrozol
Ledamin - Lenalidomida
Ledrón - Ácido Zoledrónico
Mitokebir - Mitomicina C
Paclikebir - Paclitaxel
Praxed - Pemetrexed
Rizol - Riluzol
Tazadir - Azacitidina
Topokebir - Topotecan
Vinkebir - Vinorelbina
Zolom - Temozolomida
In relation to their operations in foreign trade, official data from the
control agencies (National Administration of Customs), indicates that in the
last twelve months, imported chemical compounds and materials from China, Hong
Kong, Korea and India.
* 15 employees
BANCO CREDICOOP COOP.LTDO.
BANCO SUPERVIELLE
Credit risk February 2014:
--------------------------
BCO.CREDICOOP: $ 85.000 - Situatión 1
Situatión 1: Normal
INSURANCE:
----------
INTERACCION S.A.
Controls and consultations, nothing comes at the expense of the image of
the company. No negative legal background.
* NO COMMENTS
It is feasible for credit operations, it is advised to operate under
prudent Terms and adequate safeguards.
* OPERATION FOR MODERATE AMOUNTS AND WITH GUARANTEES.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.60.05 |
|
|
1 |
Rs.101.65 |
|
Euro |
1 |
Rs.83.07 |
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
NNA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to
overcome financial difficulties seems comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.